Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

443
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
443
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

274
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
274
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

313
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
313
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

278
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
278

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Compensation Structures, Job Satisfaction, and Retention of Facial Plastic Surgeons in Academic Practices.

Laryngoscope investigative otolaryngology·2026
Same author

Features of Importance in the Nasal Exam in Rhinoplasty.

Facial plastic surgery & aesthetic medicine·2026
Same author

Carving Out Change: Women Leading in Facial Plastic Surgery.

Facial plastic surgery & aesthetic medicine·2026
Same author

Use of Augmented Reality Technology in Cosmetic Rhinoplasty: A Feasibility Study.

Facial plastic surgery & aesthetic medicine·2026
Same author

Postoperative Pain Management in Rhinoplasty: A Double Blind Randomized Controlled Trial.

Facial plastic surgery & aesthetic medicine·2026
Same author

What to Expect With Skin Cancer Reconstruction.

JAMA otolaryngology-- head & neck surgery·2026

相关实验视频

Updated: Sep 20, 2025

Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm
06:53

Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm

Published on: July 23, 2020

5.7K

在接受GLP-1主动剂治疗的患者中,X光中脸部体积变化.

Rahul K Sharma1, Kelly L Vittetoe1, Alexander J Barna1

  • 1Vanderbilt University Medical Center, Division of Facial Plastic and Reconstructive Surgery, Nashville, Tennessee, USA.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
|May 23, 2025
PubMed
概括

减肥药物,如塞马格卢提德,可以导致面部膨胀,通常被称为"Ozempic face. 患者平均每减掉10公斤,就会失去7%的面部中部体积,主要来自表面的脂肪.

关键词:
作为GLP-1的激动剂.这就是Ozempic.面部体积面部体积医疗减肥 医学减肥 医学减肥面部中部的体积塞马格卢提德 (semaglutide) 是一种可怕的药物.

更多相关视频

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.0K
Quantification of Orofacial Phenotypes in Xenopus
09:26

Quantification of Orofacial Phenotypes in Xenopus

Published on: November 6, 2014

9.9K

相关实验视频

Last Updated: Sep 20, 2025

Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm
06:53

Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm

Published on: July 23, 2020

5.7K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

7.0K
Quantification of Orofacial Phenotypes in Xenopus
09:26

Quantification of Orofacial Phenotypes in Xenopus

Published on: November 6, 2014

9.9K

科学领域:

  • 整形外科 整形外科 整形外科
  • 医疗成像医学成像
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 面部整形外科医生观察到面部膨胀和过早衰老的患者数量增加,这可能与塞马格卢提德的使用有关.
  • 目前没有客观数据可以量化与这种减肥药物相关的中脸体积损失.

研究的目的:

  • 在使用类似葡萄糖-1 (GLP-1) 激动剂的患者中量化评估中面体积变化.
  • 为了研究体重减轻和面部体积减少的程度之间的相关性.

主要方法:

  • 一个单一的高等学术医学中心的回顾性队列研究.
  • 2017-2024年对接受GLP-1激动剂的患者的电子病历和头部/部成像 (CT/MR) 分析.
  • 测量总体,表面和深层中表面体积的变化,并对体重减轻的相关性进行统计分析.

主要成果:

  • 包括20名患者,在321天内平均体重减轻11.0公斤.
  • 面部中部总体积的中位数下降了9.0%,表面体积下降了11.0%,深部体积下降了7.0%.
  • 在体重减轻和表面体积减轻之间发现了显著的相关性 (rho=0.590,P=0.006). 线性回归表明,每10公斤体重减轻,面部中部体积损失为7%.

结论:

  • 患者可以预计,每10公斤体重损失,面部中部体积损失约为7%,主要影响表面脂肪.
  • 这项研究为"Ozempic face"现象提供了早期的定量证据,突出了GLP-1激素治疗导致的面部体积变化.